Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis

Antimicrob Agents Chemother. 2002 May;46(5):1557-60. doi: 10.1128/AAC.46.5.1557-1560.2002.

Abstract

The pharmacokinetics of piperacillin-tazobactam were investigated in eight anuric intensive care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination half-life of piperacillin was 4.3 +/- 1.2 h, and that of tazobactam was 5.6 +/- 1.3 h. The contribution of CVVHD to the overall elimination was relevant (>25%) for both drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anuria / therapy*
  • Drug Therapy, Combination / pharmacokinetics*
  • Drug Therapy, Combination / therapeutic use
  • Humans
  • Intensive Care Units*
  • Male
  • Penicillanic Acid / analogs & derivatives
  • Penicillanic Acid / pharmacokinetics*
  • Penicillanic Acid / therapeutic use
  • Piperacillin / pharmacokinetics*
  • Piperacillin / therapeutic use
  • Piperacillin, Tazobactam Drug Combination
  • Renal Dialysis / methods*

Substances

  • Piperacillin, Tazobactam Drug Combination
  • Penicillanic Acid
  • Piperacillin